May 16 - 18, 2024 Brasilia - Brazil

Main Auditorium

8 am – 8:45 am

General session 5

Coordinator:

Discussants:

8 am – 8:10 am

Dose-dense versus 3-weekly AC during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer: GBECAM 0123 – The Neo-Real Study

8:10 am – 8:20 am

Distinct expression of miRNAs and its association with survival in TNBC and non-TNBC breast tumors subtypes from a cohort of patients from South of Brazil

8:20 am – 8:30 am

Enrichment of intestinal Bifidobacterium genus is associated with residual disease among patients with early-stage HER2+ breast cancer (BC) following neoadjuvant chemotherapy (NACT)

8:30 am – 8:40 am

Discussion

8:45 am – 9:05 am

Mini Conference: When should a patient with metastatic breast cancer undergo surgery? The experience of japanese clinical oncology group

Chairwoman:

Speaker:

9:10 am – 9:50 am

Diamond Satellite Symposium – ASTRAZENECA – HER2 treat: low HER2 expression as a target in breast cancer

Speaker:

9:50 am – 10:20 am

Coffee Break

10:20 am – 10:50 am

Mini conference: The philosophical view on breast cancer treatment: from the other side of the table

Chairman:

Speaker:

10:55 am – 11:35 am

Table: How to de-escalate treatment in EC I, luminal tumors. Where do I bet my chips?

Coordinator:

Speakers:

15’ De-escalate axilla and maintain whole breast irradiation

Speakers:

15’ De-escalate radiotherapy (partial) and maintain BLS

11:35 am – 11:55 am

Mini conference: CDK4/6 inhibitors after patent expirations: how affordability can change the landscape of HR+/HER2- metastatic breast cancer

Chairman:

11:55 am – 12:35 pm

Lecture: The best of breast cancer in the last 12 months (ASCO 2023, SABS 2023 and BBCS 2024)

Chairman:

Speaker 1:

20’ Systemic

Speaker 2:

20’ Loco regional

12:35 pm – 1pm

Awarding and closing remarks